ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,041 to 4,060 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Observation Stays53 of 321

230 of 1,310

-1.0 points

-5.3 to 3.8

1,631NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Hospitalizations91 of 321

433 of 1,310

-4.7 points

-10.0 to 1.0

1,631NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Emergency Department Visits144 of 321

610 of 1,310

-1.7 points

-7.7 to 4.4

1,631NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Hospitalization, Emergency Department (ED) Visits, Observation Stays and Deaths185 of 321

781 of 1,310

-2.0 points

-8.0 to 3.9

1,631NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Deaths Among Participants13 of 321

95 of 1,310

-3.2 points

-5.5 to -0.2

1,631NCT02478359

Walk On! Physical Activity Coaching

Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With COPD-Related Hospitalizations, ED Visits, and Observation Stays48 of 321

195 of 1,310

0.1 points

-4.0 to 4.8

1,631NCT02478359

Walk On! Physical Activity Coaching

BuMA Supreme Coronary Stent System (ITT) vs Durable Polymer EES (XIENCE or Promus DES) (ITT): deaths from any cause79 of 1,086

41 of 543

-0.3 points

-3.2 to 2.3

1,629NCT03168776

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

BuMA Supreme Coronary Stent System (ITT) vs Durable Polymer EES (XIENCE or Promus DES) (ITT): serious adverse events210 of 1,086

113 of 543

-1.5 points

-5.7 to 2.6

1,629NCT03168776

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

FF/VI 100/25 µg QD vs VI 25 µg QD: Time to First On-treatment Occurrence of Moderate or Severe COPD Exacerbation69 of 806

114 of 814

-5.4 points

-8.5 to -2.4

1,620NCT02105974

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

FF/VI 100/25 µg QD vs VI 25 µg QD: serious adverse events27 of 806

35 of 814

-0.9 points

-2.9 to 1.0

1,620NCT02105974

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Aliskiren vs Placebo: serious adverse events421 of 808

435 of 810

-1.6 points

-6.4 to 3.3

1,618NCT00894387

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

All AG200-15 vs Lessina: deaths from any cause0 of 1,273

1 of 344

-0.3 points

-1.6 to 0.1

1,617NCT01181479

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

All AG200-15 vs Lessina: serious adverse events14 of 1,273

4 of 344

-0.1 points

-1.9 to 1.0

1,617NCT01181479

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

Aliskiren vs Placebo: Time to Event Analysis: Number of Patients With All-cause Mortality Hospitalized for an AHF Event Within 12 Months144 of 808

148 of 807

-0.5 points

-4.3 to 3.2

1,615NCT00894387

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

Inclisiran vs Placebo: deaths from any cause14 of 811

15 of 804

-0.1 points

-1.5 to 1.2

1,615NCT03400800

Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

Inclisiran vs Placebo: serious adverse events181 of 811

181 of 804

-0.2 points

-4.3 to 3.9

1,615NCT03400800

Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): Number of Children Who Experienced Status Epilepticus194 of 822

196 of 792

-1.1 points

-5.3 to 3.0

1,614NCT04290975

Bridging the Childhood Epilepsy Treatment Gap in Africa

Donanemab vs Placebo: Number or Participants With Anti-Donanemab Antibodies693 of 793

48 of 821

81.5 points

78.5 to 84.1

1,614NCT04437511

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Rotarix Group vs Placebo Group: serious adverse events4 of 1,082

7 of 531

-0.9 points

-2.3 to -0.1

1,613NCT00420316

Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.

Umbilical Cord Milking - Neonates vs Early Cord Clamping - Neonates: Number of Neonates Treated With Normal Saline Bolus in the First 24 Hours of Life58 of 823

56 of 790

-0.0 points

-2.6 to 2.5

1,613NCT03631940

Umbilical Cord Milking in Non-Vigorous Infants

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=203"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=203

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02478359-0f64be1d",
        "title": "Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Observation Stays",
        "summary": "53 of 321 against 230 of 1310; risk difference -1.0 points, 95% interval -5.3 to 3.8; NCT02478359, Walk On! Physical Activity Coaching",
        "record": "/library/comparisons/NCT02478359-0f64be1d",
        "nct_id": "NCT02478359",
        "kind": "outcome",
        "participants": 1631,
        "risk_difference": {
          "value": -0.01046348481605669,
          "lower": -0.05294013900048507,
          "upper": 0.03820667445678031
        },
        "group_1": "53 of 321",
        "group_2": "230 of 1,310",
        "difference": "-1.0 points",
        "interval": "-5.3 to 3.8",
        "trial_title": "Walk On! Physical Activity Coaching"
      },
      {
        "id": "NCT02478359-0f6d8204",
        "title": "Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Hospitalizations",
        "summary": "91 of 321 against 433 of 1310; risk difference -4.7 points, 95% interval -10.0 to 1.0; NCT02478359, Walk On! Physical Activity Coaching",
        "record": "/library/comparisons/NCT02478359-0f6d8204",
        "nct_id": "NCT02478359",
        "kind": "outcome",
        "participants": 1631,
        "risk_difference": {
          "value": -0.047045254571829453,
          "lower": -0.10030452249289562,
          "upper": 0.01030242820050073
        },
        "group_1": "91 of 321",
        "group_2": "433 of 1,310",
        "difference": "-4.7 points",
        "interval": "-10.0 to 1.0",
        "trial_title": "Walk On! Physical Activity Coaching"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=204",
  "request_id": "rX-LcuKBsMbvvcni"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?